Novartis to present positive data at AAN on Kesimpta's efficacy and safety

From GlobeNewswire: 2025-03-25 02:15:00

Novartis will present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis. The ALITHIOS study shows continuous Kesimpta treatment delays disability progression in RMS patients. Novartis will also highlight pipeline assets like remibrutinib and iptacopan for RMS and generalized myasthenia gravis. The data will be presented at the AAN 2025 Annual Meeting in San Diego from April 5-9, 2025. Abstracts will cover the safety and efficacy of Kesimpta over several years and real-world data on its use as a first-line treatment for RMS. Novartis aims to address neurological conditions by sharing clinical and real-world studies at the conference.



Read more at GlobeNewswire: Novartis to present new data at AAN, including seven-year